| Affimed–SVB: credit, 202101–202511 up to €25m loans in three tranches with €10m at closing plus €15m milestone-based |
2021-01-11 |
| Boehringer–Alphabet: quantum computing, 202101–202312 collab research + implementation of quantum computing in pharma RnD with Google Quantum AI |
2021-01-11 |
| Kymab–Sanofi: investment, 202101 acquisition $1.1b upfront + $350m milestones ANNOUNCED |
2021-01-11 |
| Novartis–BeiGene: tisleizumab, 202101– license $650m upfront + royalties + milestones developm + commercialisation in US, CA, MX + Europe + RU + JP |
2021-01-11 |
| Biogen–Cevec: cell line technology, 202101– license €na to Elevecta technology for manufacutring of AAV vectors for gene therapies |
2021-01-08 |
| AmpTec–Merck (DE): investment, 202101 acquisition €na of AmpTec GmbH bei Merck |
2021-01-07 |
| Cellectis–Sirion Biotech: cell/gene therapy manufacturing technology, 202101– non-excl license €na to LentiBoost technology for CAR-T cell therapies |
2021-01-07 |
| Sterna Biologicals–SEVERAL: investment, 202101 financing round Series A 2nd closing €10m bringing total Series A to €22m |
2021-01-07 |
| Eleva–Zukunftsfonds Heilbronn: investment, 202101– up to €60m for development of CPV-101 |
2021-01-06 |
| Biosun Biochemicals–BRAIN: investment, 202101 acquisition 100% €na by BRAIN AG |
2021-01-01 |
| Qiagen–Wellcome Trust: COSMIC Database, 202101– distribution excl rights to license + distribute COSMIC for commercial use |
2021-01-01 |
| SomaLogic–Novartis: investment, 202012 financing round Series A 2nd closing totalling addit $81m incl Novartis |
2020-12-22 |
| SomaLogic–SEVERAL: investment, 202012 financing round Series A 2nd closing additional $81m bringing total Series A to $204m or $214m |
2020-12-22 |
| Evotec–Alloy Therapeutics: transgenic mouse technolgy, 202012– supply access to ATX-Gx platform to expand Evotec antibody discovery platform |
2020-12-21 |
| Peptilogics–Angermayer Group: investment, 202012 financing round Series B totalling $35.4m incl new + lead investor Presight Capital |
2020-12-21 |
| Peptilogics–SEVERAL: investment, 202012 financing round Series B $35.4m led by Presight Capital |
2020-12-21 |
| Cadent Therapeutics–Novartis: investment, 202012– acquisition $210m upfront + $560m milestones ANNOUNCED |
2020-12-17 |
| Neuron23–SEVERAL: investment, 202012 financing round Series B $80m led by new investor Redmile Group |
2020-12-16 |
| MYR GmbH–Gilead Sciences: investment, 202012 acquisition €1.15b in cash + €300m milestones of MYR GmbH by Gilead Sciences Inc |
2020-12-10 |
| NBE Therapeutics–Boehringer: investment, 202012– acquisition up to €1.18b by Boehringer |
2020-12-10 |
| Resolve Biosciences–Alafi Capital: investment, 202012 financing round Series A totalling $24m incl co-investor Alafi Capital |
2020-12-10 |
| Resolve Biosciences–Bioscribe: public relations, 202012 service existent by Bioscribe |
2020-12-10 |
| Resolve Biosciences–High-Tech Gründerfonds: investment, 202012 financing round Series A totalling $24m incl co-investor HTGF |
2020-12-10 |
| Resolve Biosciences–MasterMind Advisory Services: investment, 202012 financing round Series A totalling $24m incl co-lead investor MasterMind |
2020-12-10 |
| Resolve Biosciences–PERSON: investment, 202012 financing round Series A totalling $24m incl co-investor John Shoffner |
2020-12-10 |
| Resolve Biosciences–PS Capital Management: investment, 202012 financing round Series A totalling $24m incl co-lead investor PS Capital |
2020-12-10 |
| Resolve Biosciences–SEVERAL: investment, 202012 financing round Series A $24m co-led by PS Capital Management + MasterMind Advisory Services |
2020-12-10 |
| Curexsys–Evotec: investment, 202012 seed financing round totalling €8.2m incl Evotec acquiring 37% equity stake |
2020-12-09 |
| Curexsys–Sartorius: investment, 202012 seed financing round totalling €8.2m incl Sartorius acquiring 21% equity stake |
2020-12-09 |
| Curexsys–SEVERAL: investment, 202012 seed financing round €8.2m led by Evotec + Sartorius |
2020-12-09 |
| Novartis–RetinAI Medical: AI-based image analysis, 202012– collab expansion master agreement using RetinAI Discovery platform in ophthalmology |
2020-12-08 |
| RetinAI Medical–Charles Consultants: public relations, 202012 service existent by Sue Charles |
2020-12-08 |
| Biomes NGS–GPS Ventures: investment, 202012 pre-series A investment €2m from GPS Ventures GmbH |
2020-12-07 |
| Boehringer–Proxygen: molecular glue degraders, 202012– collab + license agreem developm in combi with PROTACs against oncogenic targets |
2020-12-07 |
| MaaT Pharma–Céleste Management: investment, 202012 financing round Series B extension totalling €7.35m incl new + co-investor Céleste Management |
2020-12-01 |
| MaaT Pharma–SEVERAL: investment, 202012 financing round Series B extension €7.35m led by Bpifrance bringing total Series B to €25.35m |
2020-12-01 |
| MaaT Pharma–SkyViews Life Science: investment, 202012 financing round Series B extension totalling €7.35m incl new + co-investor SkyViews Life Science |
2020-12-01 |
| Slack Technologies–Salesforce: investment, 202012– acquisition $27.7b in cash + shares of Slack by Salesforce ANNOUNCED |
2020-12-01 |
| Adrenomed–HBM: investment, 202011 financing round Series E totalling €22.2m incl existing + co-lead investor HBM Healthcare Investments |
2020-11-30 |
| Adrenomed–SEVERAL: investment, 202011 financing round Series E €22.2m co-led by Wellington Partners + HBM |
2020-11-30 |
| Adrenomed–Wellington Partners: investment, 202011 financing round Series E totalling €22.2m incl existing + co-lead investor Wellington Partners |
2020-11-30 |
| BioNTech–InstaDeep: AI-based drug discovery, 2019– collab initiated in 2019 |
2020-11-25 |
| BioNTech–InstaDeep: AI-based drug discovery, 202011– strategic collab incl joined AI Innovation Lab to develop immunotherapies |
2020-11-25 |
| Emergence Therapeutics–High-Tech Gründerfonds: investment, 202011 follow-on seed financing round incl lead investor HTGF |
2020-11-25 |
| Emergence Therapeutics–SEVERAL: investment, 202011 follow-on seed financing round led by HTGF |
2020-11-25 |
| Innatera Nanosystems–btov Partners: investment, 202011 seed financing round totalling €5m incl co-lead investor btov Industrial Technologies Fund |
2020-11-25 |
| Innatera Nanosystems–MIG Fonds: investment, 202011 seed financing round totalling €5m incl co-lead investor MIG Verwaltungs AG |
2020-11-25 |
| Innatera Nanosystems–SEVERAL: investment, 202011 seed financing round €5m co-lead by MIG Verwaltungs AG + btov Industrial Technologies Fund |
2020-11-25 |
| ATAI Life Sciences–SEVERAL: investment, 202011 financing round Series $125m incl $32m converted debt co-led by Apeiron + Peter Thiel + Catalio Capital |
2020-11-23 |
| Voluntis–Debiopharm: investment, 202011 capital increase totalling €5.93m incl €3.92m from new + lead investor Debiopharm Innovation Fund |
2020-11-23 |
| Voluntis–Indigo (Eric Carreel): investment, 202011 capital increase totalling €5.93m incl €1m from existing + co-investor Indigo |
2020-11-23 |
| Voluntis–SEVERAL: investment, 202011 capital increase €5.93m net €5.7m led by Debiopharm Innovation Fund |
2020-11-23 |
| SynOx Therapeutics–Roche: emactuzumab, 202011 excl ww rights for developm + production + commercialisation |
2020-11-19 |
| SynOx Therapeutics–SEVERAL: investment, 202011 financing round Series A €37m co-led by HealthCap + Medicxi with Forbion + Gimv |
2020-11-19 |
| Pharvaris–Bain Capital: investment, 202011 financing round Series C totalling $80m incl existing + co-investor Bain Capital Life Sciences |
2020-11-18 |
| Pharvaris–Cormorant Asset Management: investment, 202011 financing round Series C totalling $80m incl new + co-investor Cormorant Asset Management |
2020-11-18 |
| Pharvaris–Foresite Capital: investment, 202011 financing round Series C totalling $80m incl existing + co-investor Foresite Capital |
2020-11-18 |
| Pharvaris–General Atlantic: investment, 202011 financing round Series C totalling $80m incl new + co-lead investor General Atlantic |
2020-11-18 |
| Pharvaris–Rockefeller: investment, 202011 financing round Series C totalling $80m incl existing + co-investor Venrock Health Capital Partners |
2020-11-18 |
| Pharvaris–SEVERAL: investment, 202011 financing round Series C $80m co-led by Viking Global Investors + General Atlantic |
2020-11-18 |
| Pharvaris–VenBio: investment, 202011 financing round Series C totalling $80m incl existing + co-investor venBio Partners |
2020-11-18 |
| Pharvaris–Viking Global Investors: investment, 202011 financing round Series C totalling $80m incl new + co-lead investor Viking Global Investors |
2020-11-18 |
| Roche–Lead Pharma: small-molecule immuno modulators, 202011– collab + license agreem up to €260m incl €10m upfront plus royalties |
2020-11-16 |
| m2p-labs–Danaher: investment, 202011 acquisition of m2p-biolabs by Beckman Coulter Life Sciences |
2020-11-12 |
| Metagenomi–Agent Capital: investment, 202011 financing round Series A totalling $65m incl co-investor Agent Capital |
2020-11-12 |
| Metagenomi–Bayer: investment, 202011 financing round Series A totalling $65m incl co-lead investor Leaps by Bayer |
2020-11-12 |
| Metagenomi–HOF Capital: investment, 202011 financing round Series A totalling $65m incl co-investor HOF Capital |
2020-11-12 |
| Metagenomi–Humboldt Fund: investment, 202011 financing round Series A totalling $65m incl co-lead investor Humboldt Fund |
2020-11-12 |
| Metagenomi–InCube Ventures: investment, 202011 financing round Series A totalling $65m incl co-investor InCube Ventures |
2020-11-12 |
| Metagenomi–SEVERAL: investment, 202011 financing round Series A $65m co-led by Leaps by Bayer + Humboldt Fund |
2020-11-12 |
| Metagenomi–Sozo Ventures: investment, 202011 financing round Series A totalling $65m incl co-investor Sozo Ventures |
2020-11-12 |
| Synendos Therapeutics–SEVERAL: investment, 202011 financing round Series A CHF20m co-led by Kurma Partners + Sunstone LSV |
2020-11-12 |
| MorphoSys–Cherry Biolabs: Hemibody technology, 202011– license €na to apply Hemibody technology to six exclusive targets |
2020-11-11 |
| Catalym–Bavaria (govt): investment, 202011 financing round Series B totalling €50m incl co-investor Wachstumsfonds Bayern |
2020-11-10 |
| Catalym–Germany (govt): investment, 202011 financing round Series B totalling €50m incl co-investor Coparion |
2020-11-10 |
| Catalym–Novartis: investment, 202011 financing round Series B totalling €50m incl co-investor Novartis Venture Fund |
2020-11-10 |
| Catalym–SEVERAL: investment, 202011 financing round Series B €50m led by Vesalius Biocapital III |
2020-11-10 |
| Catalym–Vesalius Biocapital: investment, 202011 financing round Series B totalling €50m incl lead investor Vesalius Biocapital III |
2020-11-10 |
| Roche–Cevec: cell line technology, 202011– license €na to Elevecta technology for manufacutring of AAV vectors for gene therapies |
2020-11-10 |
| Apeiron–Domainex: drug discovery services, 202011– collab expansion supply of lead optimisation services for Cbl-b targeting APN431 compound series |
2020-11-09 |
| Vera Therapeutics–Merck (DE): atacicept, 202011– license for 10% equity in Vera + €605m milestones + royalties |
2020-11-09 |
| Vera Therapeutics–Merck (DE): investment, 202011 Merck reveices 10% equity in Vera Tx as part of license deal for atacicept |
2020-11-09 |
| Memo Therapeutics–Bernina BioInvest: investment, 202011 financing round Series B totalling CHF14m incl new + co-investor Bernina BioInvest |
2020-11-05 |
| Memo Therapeutics–Halsin Partners: public relations, 202011 service existent by Halsin Partners |
2020-11-05 |
| Memo Therapeutics–Jaquet Partners: investment, 202011 financing round Series B totalling CHF14m incl existing + co-investor Jaquet Partners |
2020-11-05 |
| Memo Therapeutics–OTHER: investment, 202011 financing round Series B totalling CHF14m incl new private investors |
2020-11-05 |
| Memo Therapeutics–Redalpine: investment, 202011 financing round Series B totalling CHF14m incl existing + co-investor Redalpine |
2020-11-05 |
| Memo Therapeutics–Schroders: investment, 202011 financing round Series B totalling CHF14m incl existing + co-investor Schroder Adveq |
2020-11-05 |
| Memo Therapeutics–SEVERAL: investment, 202011 financing round Series B CHF14m led by Swisscanto by ZKB |
2020-11-05 |
| Memo Therapeutics–Verve Capital Partners: investment, 202011 financing round Series B totalling CHF14m incl existing + co-investor Investiere |
2020-11-05 |
| Memo Therapeutics–Zürcher Kantonalbank: investment, 202011 financing round Series B totalling CHF14m incl existing + lead investor Swisscanto by ZKB |
2020-11-05 |
| Corlieve Therapeutics–SEVERAL: investment, 202011 seed financing round from Kurma Partners + Idinvest Partners + Pureos Bioventures |
2020-11-02 |
| Kiadis–Sanofi: investment, 202011– cash tender offer €308m for Kiadis Pharma NV at €5.45 per share (272% premium over closing price on 30 Oct) |
2020-11-02 |
| Polaris Science (SG)–Nynomic: plant phenotyping, 202011– distribution in Singapore + Malaysia of LemnaTec solutions for phenotyping + seed testing |
2020-11-01 |
| TVM–Lilly: investment, 202010 final closing totalling $478m of fund TVM Life Science Innovation II incl investor Eli Lilly |
2020-10-27 |
| TVM–OCP Capital: investment banking, –202010 supply service OCP supports fund raising for $478m TMV LSI II fund |
2020-10-27 |
| TVM–SEVERAL: investment, 202010 final closing of $478m of fund TVM Life Science Innovation II incl Eli Lilly |
2020-10-27 |
| AskBio–Bayer: investment, 202010 acquisition by Bayer for $2b upfront plus $2b milestones |
2020-10-26 |
| Eternygen–SEVERAL: investment, 202010 financing round Series A2 1st closing €5m led by Evotec |
2020-10-26 |
| MD Biosciences–MLM Medical Labs: investment, 202010 acquisition of MD Biosciences Inc by MLM Medical Labs |
2020-10-26 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo-2019.png){kind=logo}
Date
![Picture [iito] Made Without Love 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-made-without-love.jpg)
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
